Procalcitonin Assay
PRI is the FDA product code for Procalcitonin Assay, a class II device type, regulated under 21 CFR 866.3215. FDA's definition for this code reads: "To aid in decision making on antibiotic therapy, including antibiotic initiation and discontinuation, for inpatients or patients in the Emergency Department, with suspected or confirmed lower respiratory tract infections (LRTI) defined as community-acquired pneumonia (CAP), acute bronchitis, and acute exacerbation of...". As of , FDA records hold 8 510(k) clearances under this code, the most recent dated , and one recall.
Classification record
- Product code
- PRI
- Device name
- Procalcitonin Assay
- FDA definition
- To aid in decision making on antibiotic therapy, including antibiotic initiation and discontinuation, for inpatients or patients in the Emergency Department, with suspected or confirmed lower respiratory tract infections (LRTI) defined as community-acquired pneumonia (CAP), acute bronchitis, and acute exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD).
- Regulation
- 21 CFR 866.3215
- Device class
- Class II
- Review panel
- Microbiology
- Submission type
- 510(k)
- Implant
- No
- Life sustaining or supporting
- No
- GMP exempt
- No
- Third party review eligible
- No
- Ingested clearances
- 8
- Ingested recalls
- 1
Clearances, product code PRI
By decision yearShow the numbers
| Year | Clearances |
|---|---|
| 2017 | 4 |
| 2018 | 2 |
| 2020 | 1 |
| 2022 | 1 |
Applicants with the most clearances
Product code PRI| Applicant | Clearances |
|---|---|
| Roche Diagnostics GmbH | 2 |
| B.R.A.H.M.S GmbH | 1 |
| Diasorin Inc. | 1 |
| Fisher Diagnostics | 1 |
| Fujirebio Diagnostics, Inc. | 1 |
| Siemens Healthcare Diagnostics Inc. | 1 |
| bioMerieux, Inc. | 1 |
Companies listing this code with FDA
Companies whose registered establishments list this codeFIRST ARTICLE / WEEKLY
What cleared, what was recalled, and what changed in the standards. One edition a week for the people who make medical devices.
